skip to main content

Spironolactone safety in heart failure — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardCardiovascular TherapeuticsSpironolactone safety in heart failureGPhC CRA

A patient with HFrEF starts spironolactone after normal baseline potassium and renal results. Which early monitoring schedule best detects treatment-related hyperkalaemia?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Renal function and electrolytes after 1 week, then monthly initially

Spironolactone can cause early hyperkalaemia and renal deterioration, especially with renin–angiotensin-system treatment. Renal function and electrolytes are checked after about 1 week, monthly for the first 3 months and then every 3 to 6 months once stable, with closer review after dose or clinical changes.

Reference: BNF: spironolactone: https://bnf.nice.org.uk/drugs/spironolactone/